Hallucinogen Use Disorders.
Hardaway R, Schweitzer J, Suzuki J.
Child Adolesc Psychiatr Clin N Am. 2016 Jul;25(3):489-96. doi: 10.1016/j.chc.2016.03.006. Epub 2016 Apr 18.
Time-trends in cocaine, hallucinogen, amphetamine, and sedative/anxiolytic/hypnotic use disorder hospitalizations in rheumatic diseases: a national time-trends study.
Singh JA.
Clin Rheumatol. 2021 Jul;40(7):3007-3014. doi: 10.1007/s10067-021-05715-6. Epub 2021 Mar 30.
The Therapeutic Potential of Psilocybin.
Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, Ngwa W, Gordon L.
Molecules. 2021 May 15;26(10):2948. doi: 10.3390/molecules26102948.
Human hallucinogen research: guidelines for safety.
Johnson M, Richards W, Griffiths R.
J Psychopharmacol. 2008 Aug;22(6):603-20. doi: 10.1177/0269881108093587. Epub 2008 Jul 1.
Psychedelics.
Kelmendi B, Kaye AP, Pittenger C, Kwan AC.
Curr Biol. 2022 Jan 24;32(2):R63-R67. doi: 10.1016/j.cub.2021.12.009.
The pharmacology of psilocybin.
Passie T, Seifert J, Schneider U, Emrich HM.
Addict Biol. 2002 Oct;7(4):357-64. doi: 10.1080/1355621021000005937.
Towards an understanding of psychedelic-induced neuroplasticity.
Calder AE, Hasler G.
Neuropsychopharmacology. 2023 Jan;48(1):104-112. doi: 10.1038/s41386-022-01389-z. Epub 2022 Sep 19.
Psilocybin for Trauma-Related Disorders.
Khan AJ, Bradley E, O'Donovan A, Woolley J.
Curr Top Behav Neurosci. 2022;56:319-332. doi: 10.1007/7854_2022_366.
Psychedelic-inspired approaches for treating neurodegenerative disorders.
Saeger HN, Olson DE.
J Neurochem. 2022 Jul;162(1):109-127. doi: 10.1111/jnc.15544. Epub 2021 Dec 5.
Psychedelics and Psychedelic-Assisted Psychotherapy.
Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, Kalin NH, McDonald WM; the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research.
Am J Psychiatry. 2020 May 1;177(5):391-410. doi: 10.1176/appi.ajp.2019.19010035. Epub 2020 Feb 26.
